mice lethally infected with the c56 strain of toxoplasma gondii and treated with purified recombinant murine tumour necrosis factor ( tnf , 1 microgram/day/mouse for 8 days ) , recombinant human interleukin-1 ( il-1 alpha or il-1 beta , 100 ng/day/mouse for 5 days ) or a single dose of a combination of tnf ( 1 microgram/mouse ) and il-1 alpha or il-1 beta ( 100 ng/mouse ) were significantly protected against death ( p less than 0.05-0.001 , as compared with untreated infected controls ) .
C0021755
recombinant
C0600251
il-1 alpha